A number of studies have shown that the transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) into the thinned infarct wall improves regional wall motion. In this study, we hypothesized that the injection of biomaterials and MSCs into the infarcted myocardium can preserve left ventricular (LV) function. To test this hypothesis, anterior acute myocardial infarction (AMI) was induced in 34 rabbits and BMSCs with hydrogel composite were prepared. One week after inducing AMI, 28 of the 34 rabbits were divided into four groups (Groups AeD; three rabbits were used for bone marrow aspiration, and three rabbits died) and all received an epicardial injection. Group A received BMSCs with hydrogel composite marked by 5-bromodeoxyuridine (BrdU); Group B received BMSCs only marked by BrdU; Group C received hydrogel only marked by BrdU; and Group D was the control group, which received fetal bovine serum. Echocardiography was performed before AMI was induced, 1 week after AMI, and 4 weeks after the epicardial injection. The results were compared with those before AMI, and the rabbits of all the four groups had significantly larger LV end-diastolic diameter (LVDd), thinner anterior wall (AW), lower LV ejection fraction (LVEF), lower V S and V E (p < 0.05) 1 week after AMI, which were more significant in Group A (p < 0.05). Compared with 1 week after AMI, Group A and Group B had significantly smaller LVDd, thicker AW, larger LVEF, larger V S and V E (p < 0.05) 4 weeks after the epicardial injection, which were more significant in Group A (p < 0.05); however, there was no significant difference in Group C and Group D. These results suggested that BMSCs with hydrogel composite could serve as an injectable biomaterial that prevents LV remodeling and dilation, and improves local systolic and diastolic function after AMI.
Introduction
Left ventricle (LV) remodeling and subsequent heart failure after myocardial infarction (MI) are often progressive. This process results in a sequence of molecular, cellular, and physiological responses that lead to LV dilation, which may eventually lead to decompensation with congestive heart failure [1] . Paradoxical systolic bulging caused by infarct expansion and thinning can impair LV systolic function [2] .
Recently, transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) into the thinned infarct wall to replace the necrotic cardiomyocytes has been shown to improve regional wall motion, particularly the reduction in the degree of dyskinesis of the infarct zone [3e5] . Experimental evidence shows that MSCs are a promising cell type for mediating cell therapy for MI. These cells retain the capacity to produce cells of all three germ layers and, under specific culture conditions; MSCs can differentiate into synchronously beating cardiomyocytes [6] . Although the transdifferentiation ability of BMSCs into cardiomyocytes has been questioned [7] , MSCs still hold promise in cell-based therapy for MI because they can secrete a variety of cytokines and growth factors that stimulate angiogenesis, prevent myocardial death in ischemic conditions, and attract stem cell homing [8e10] . Although the underlying mechanisms are a matter of debate, engraftment of MSCs into ischemic myocardial tissue and their consecutive paracrine effects are intended to substantially attenuate morphological and functional postinfarction remodeling [9] .
However, the fraction of transplanted cells retained and engrafted within the myocardium has been found to be below 3% shortly after transplantation [11, 12] . Polymeric hydrogels are crosslinked polymer networks, which can take up a large quantity of water, and render them biocompatible, similar to soft tissues [13] . Intelligent hydrogels that are capable of changing their shape, structure, or volume of exposure to external stimuli such as pH [14, 15] , temperature [16, 17] , antigen [18] , electric field [19] , and photofield [20] have also been developed. These hydrogels are advantageous in clinical applications due to their fluidity, which enables the materials to be introduced into the site-specific organ, tissue, or body cavity with improved patient applicability and comfort [17] .
The objective of this study was to demonstrate the feasibility and tolerability of injecting BMSCs with a novel synthetic hydrogel into an infarcted wall of a rabbit and also to investigate whether hydrogel implantation improves an infracted LV function.
Materials and methods
The experiments were performed in 34 male rabbits: three rabbits, of 1.5-kg body weight, were used for the harvest of BMSCs; the other 31 rabbits, with an initial body weight of 2.2e2.6 kg, were used for the MI model. All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S National Institutes of Health, and the study protocol was approved by the Institutional Animal Care Committee of Wuhan University, People's Republic of China.
Preparation of BMSCs
Bone marrow was aspirated from the tibia of 2-month-old rabbits with an 18-gauge needle connected to a syringe containing heparin. Bone marrow cells were flushed and cultured with Dulbecco's modified Eagle's medium (DMEM)/ F12 medium (Gibco) supplemented with 20% fetal bovine serum (FBS; Gibco) and penicillin (100 U/mL)/streptomycin (100 U/mL) at 37 C in humid air with 5% CO 2 . Two days after sowing, the BMSCs had adhered to the bottom of culture plates and the hematopoietic cells remained suspended in the medium. The nonadherent cells were removed by changing the medium at 48 hours and every 3 days thereafter. BMSCs were labeled with 25 mg/mL 5bromodeoxyuridine (BrdU) 10 mL for 24 hours.
Cell encapsulation of the hydrogel
The poly(ethylene glycol)-b-polycaprolactone-(dodecanedioic acid)-polycaprolactone-poly(ethylene glycol) (MPEGe PCLeMPEG) solution (10 wt.%) and a-cyclodextrin (a-CD) solution (10 wt.%) were sterilized in an autoclave before use.
BMSCs were seeded onto 96-well plates at a density of 1 Â 10 4 cells/well. After 12 hours of incubation for adhesion, the culture medium was replaced by 200 mL of DMEM/ F12 containing particular concentrations of the a-CD/ MPEGePCLeMPEG hydrogel co-polymer, followed by incubation at 37 C in humidified 5% CO 2 atmosphere for 48 hours. The medium with polymer was then replaced with fresh medium containing 20 mL of MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (5 mg/mL) and incubated for 4 hours. The supernatant was aspirated and the formazan crystals were set aside in 200 mL of dimethyl sulfoxide. Aliquots were drawn from each well and the optical density (OD) was spectrophotometrically measured in a Microplate Reader Model 550 (Bio-Rad, USA) at 490 nm. Untreated cells were chosen as the control with 100% viability, and cells without the addition of MTT were used as a blank to calibrate the spectrophotometer to zero absorbance. The relative cell viability (%) was calculated using the formula OD treated / OD control by comparing the control cells.
BMSCs were removed from the culture flasks with trypsin and centrifuged to make a pellet (5 Â 10 6 cells/shot). The cell pellet was resuspended in a-CD solution with gentle mixing using a micropipettor. The cell/a-CD solution mixtures were then aspirated and mixed with MPEGePCLeM-PEG solution to form a solid hydrogel in a six-well plate. Fresh medium was then added to the plates. After incubation for 3 days, the medium in the well was pipetted out. The hydrogel with cells is washed three times with phosphate-buffered saline, fixed in 2.5% glutaraldehyde for 2 hours, dehydrated with a graded ethanol series, frozen under liquid nitrogen, and freeze dried. After gold coating, the morphology of cells in the hydrogel was examined by scanning electron microscopy.
Animal model of MI
Rabbits were anesthetized with an intravenous injection of 3% pentobarbital sodium (30 mg/kg). The rabbits' heart was exposed by performing a 3e5-cm left lateral thoracotomy, and the left anterior descending coronary artery was ligated by a 5-0 silk suture, and the chest was closed. The operation was performed with electrocardiogram monitoring, and rabbits with obvious ST segment elevation in lead V 1 eV 6 were considered as successful MI models. Penicillin G benzathine (800,000 U/day) was intramuscularly administered for 3 days after the operation.
Implantation surgery
Seven days after inducing MI, the rabbits were randomized into the following four groups: the BMSCs þ hydrogel group (Group A, n Z 7); the BMSCs group (Group B, n Z 7); the hydrogel group (Group C, n Z 7); and the control group (Group D, n Z 7).
After anesthetization, the hearts were exposed through a second thoracotomy, and 200 mL solutions were injected into four sites in the infarcted myocardium (each injection Z 50 mL). In Group A, 2 Â 10 7 BMSCs were suspended in 100 mL of a-CD solution (10 wt.%, dissolved in culture medium), delivered with 100 mL of MPEGePCLeM-PEG solution through a Duploject applicator, which contained the two parts in separate syringes and provided simultaneous mixing during delivery. In Group B, 200 mL of 2 Â 10 7 BMSCs were injected into the myocardium. In Group C, 200 mL of DMEM/F12 medium without BMSCs were injected into the myocardium. In Group D, 200 mL FBS were injected into the myocardium.
Conventional echocardiography and quantitative tissue velocity imaging
The LV dimension and function were measured by echocardiography (GE Vivid 7, USA; M10S transducer, 4e12 MHz). The echocardiography examination was performed before MI, 7 days after MI, and 28 days after the implantation surgery by two researchers blinded to the treatment allocation. The LV end-diastolic diameter (LVDd), anterior wall thickness (AWT) in end diastole, and LV ejection fraction (LVEF) were measured from at least three consecutive cardiac cycles. Tissue velocity imaging (TVI) at two-chamber apical view was stored for offline analysis. Using quantitative TVI (QTVI), the sampling point was located on the endocardial myocardium of AW at the middle and basal levels. From the QTVI curve, velocity in systole (V S ) and velocity in early diastole (V E ) were measured in at least three consecutive cardiac cycles.
Histology and immunohistochemistry
Four weeks after the treatment, the rabbit LVs were retrieved and freshly frozen in Tissue-Tek O.C.T. freezing medium, and then sectioned at five different transversal levels around the injection site. Fluorescence microscopy was used to detect BrdU-labeled transplanted BMSCs around the injection sites. The sections were then stained with Masson's trichrome methods. In each section, the infarcted and noninfarcted areas were measured by automated computer image analysis. The infarct size (%) was calculated from the ratio of surface area of infarct wall and the entire surface area of the LV.
For immunohistochemical analysis, 4-mm-thick sections were stained using antibodies against a-smooth muscle actin (a-SMA, 1:100 dilutions; Boster, China) to label mature blood vessels. The sections were incubated with the primary antibody diluted in staining buffer, and then incubated again with a horseradish peroxidase-conjugated goateanti-mouse secondary antibody (Boster; China) to visualize labeled vessels. Hematoxylin was used for counterstaining. Blood vessel density was expressed as the number of vessels at 200 Â high-power magnification fields.
Statistical analysis
All results were presented as the mean AE standard deviation. The data were compared and intergroup differences were analyzed by one-way analysis of variance with the post hoc Bonferroni test, and variance ratio (F ) was calculated. Statistical analyses were performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was taken to be significant.
Results
A total of 34 rabbits were initially included in this study. Three rabbits were used for bone marrow aspiration, and three rabbits died during or immediately after the infarct surgery because of ventricular fibrillation. After the surgery, there was 100% survival in all groups. The LV function and volume measurements and histological analysis were performed on these 28 rabbits.
Effects of hydrogel implantation on conventional echocardiography parameters after MI
As shown in Table 1 , compared with results before MI, there was a decrease in LV dilation, AWT thinning, and LVEF in all rabbits 7 days after MI. Twenty-eight days after the implantation surgery, BMSCs þ hydrogel or BMSCs injection inhibited LV dilation, AWT thinning, and LVEF decrease following MI: in the BMSCs þ hydrogel group, LVDd, AWT, and LVEF were 12.03 AE 1.25 mm, 1.80 AE 0.28 mm, and 69.61% AE 6.92%, respectively. In the BMSCs group, LVDd, AWT, and LVEF were 12.81 AE 1.24 mm, 1.71 AE 0.30 mm, and 65.16% AE 7.42%, respectively. However, the BMSCs þ hydrogel group had a trend for smaller LVDd, thicker AWT, and significantly greater LVEF compared with the BMSCs group. There was no significant improvement in the hydrogel and control groups 28 days after the implantation surgery ( Table 1) .
Effects of hydrogel implantation on QTVI parameters after MI
Compared with results before MI, rabbits of all four groups had significantly lower V S and V E (p < 0.05) 7 days after MI. Compared with 7 days after MI, the BMSCs þ hydrogel group or BMSCs group had significantly larger V S and V E (p < 0.05) 28 days after the implantation surgery, which were more significant in Group A (p < 0.05); but there were no Table 2 Comparison of QTVI parameters in four rabbit groups before AMI, 1 week after AMI and 4 weeks after implantation surgery.
Group
Before AMI 1 week after AMI 4 weeks after implantation surgery 
Histology and immunohistochemistry
Four weeks after the surgery, examination by fluorescence microscopy showed that BMSCs labeled with BrdU before implantation were detected around the injection sites in both groups of BMSCs implanted with and without hydrogel, which suggested that the implanted cells retained and survived in the infarction sites. Statistical analysis showed a significant increase in the BrdU-labeled cells in Group A (BMSCs þ hydrogel, 2147 AE 241 mm À2 ) when compared with Group B (BMSCs, 851 AE 149 mm À2 ); Groups C and D had no BMSCs labeled with BrdU around the injection sites. The infarct sizes in Groups A, B, C, and D were 19.45% AE 2.36%, 24.12% AE 1.97%, 29.52% AE 2.24%, and 30.01% AE 2.13%, respectively. Statistical analysis showed a significant reduction in the infarct size after cell implantation (Groups A and B vs. Groups C and D, p < 0.05). The injection of BMSCs with hydrogel further reduced the infarct size when compared with implantation of BMSCs alone (vessels at the border of infarct area were labeled with anti-a-SMA, which is expressed in smooth muscle cells in mature blood vessels) [21] . A larger number of microvessels at the border of the infarct area were positively stained in the BMSCs group implanted with hydrogel than in the other three groups. In addition, the number of microvessels in the cell group was significantly larger than the control (p < 0.05; Figs. 5 and 6 ).
Discussion
Myocardial cell therapy with BMSCs is an emerging therapeutic option after MI [5] . BMSCs can be transplanted autologously without the need for immunosuppression and expanded in vitro. Although the underlying mechanisms are a matter of debate, engraftment of BMSCs into ischemic myocardial tissue and their consecutive paracrine effects are intended to substantially attenuate morphological and functional postinfarction remodeling [9] . However, the fraction of transplanted cells retained and engrafted within the myocardium has been found to be below 3% shortly after transplantation [11, 12] . Improving the efficacy of a sustained myocardial cell delivery might result in improved functional outcome. Therefore, the improvement of transplantation efficacy might positively influence their therapeutic potential.
Our results indicate that BMSCs transplant retention and survival in infarcted myocardium were enhanced by injection of BMSCs with a-CD/MPEGePCLeMPEG hydrogel, which can improve the LV remodeling and function more significantly than transplant of BMSCs alone. The study by Mathieu and co-workers showed that the cardiac function varied over the 8 weeks, especially in the hydrogel group, which showed improved cardiac function at 4 weeks but were even worse at 8 weeks after therapy [22] . Our results show that all the cardiac morphology and function improved significantly in groups with BMSCs therapy, while there was no change in groups with hydrogel or controls. Maybe these differences are due to different animal models and follow-up time. In the first weeks of MI, the activation of matrix metalloproteases damaged the cardiac extracellular matrix (ECM), which might inhibit the adhesion of transplanted cells [23, 24] . The rapid gelation kinetics of the hydrogel allowed effective entrapment of BMSCs at the site of injection [25] . Furthermore, the polymer chains of the hydrogel were highly hydrated, making the hydrogel similar to natural tissues and suitable for cell growth [26] . In the in vitro study, no significant cytotoxicity was found in the hydrogel, and the morphology of the BMSCs in the hydrogel was spindle-like, which indicated that they were in a viable state.
A number of studies have demonstrated that BMSCs contain endothelial precursors, and the implantation of BMSCs could induce neovascularization in ischemic myocardium [27, 28] . The a-CD/MPEGePCLeMPEG hydrogel did not induce angiogenesis, but we demonstrated that implantation of BMSCs using the hydrogel increased vessel density around the border of the infarct compared with BMSCs implanted alone as confirmed in our previous study [29] . This favorable result could be explained as the consequence of increased cell retention and survival induced by the hydrogel. By increasing the vessel density, the therapeutic effect was subsequently raised. Therefore, we could demonstrate that injection of BMSCs with a-CD/ MPEGePCLeMPEG hydrogel could enhance the beneficial effects of BMSC implantation on cardiac function, contractility, and remodeling. The underlying mechanism is likely to increase cell retention and survival when cells were implanted with hydrogel, which induces more neovascular formation in the infarcted myocardium.
Our results show that the combination of the two therapies may have some synergistic benefits that cannot be achieved from either of them alone: hydrogel can enhance cell retention and serve as an ECM in which the transplanted cells can grow. Although this study shows that intramyocardial injection of BMSCs with a-CD/MPEGePCLeMPEG hydrogel after MI could increase cell retention and vessel density at the border of the infarct area, improve LV function, and prevent LV remodeling, the long-term effects of this therapy and the secretion and differentiation of implanted BMSCs in hydrogel still need further investigation.
Conclusion
This study shows that intramyocardial injection of BMSCs with a-CD/MPEGePCLeMPEG hydrogel into infarcted myocardium in rabbits could improve the impaired cardiac function compared with implantation of BMSCs only. Our study may have implications for further experimental and clinical studies. 
